Gamalei Centre allowed new trials of COVID-19 vaccine

By | August 25, 2020
The Ministry of Health has issued permission to conduct a post-registration clinical study of the vaccine

The Ministry of Health has issued permission to conduct a post-registration clinical study of the vaccine. It will be attended by 40,000 people. National Research Center for Epidemiology and Microbiology. Academician N.F. Gamalei received permission to conduct a post-registration clinical study of the coronavirus vaccine. This is stated in the statement of the Ministry of Health, which was received by RBC.” The Ministry of Health of Russia has issued permission to conduct a post-registration clinical study of the vaccine to prevent the new coronavirus infection “Gam-Kovid-Vac” (brand “Sputnik V” – RBC) to its developer – the National Research Center for Epidemiology and Microbiology. Gamalei of the Russian Ministry of Health,” the statement said.

The study will involve 40,000 people. volunteers, all of them should be over 18 years old. Participation in the study will last six months from the day of vaccination, it will be held on the basis of Moscow medical institutions.

Gam-Kovid-Vac was the first registered coronavirus vaccine in Russia and the world. This was announced by President Vladimir Putin on August 11.

The vaccine is designed for intramuscular administration and consists of two components in vials of 0.5 ml. The head of the Gamalei center, Alexander Ginzburg, promised that the immunity that a person will have after vaccination will last for about two years.

He also reported that the bulk of the vaccine will be used in the post-registration study. “After that, the rest of the production will go into civilian circulation. The delay is two or three weeks, maybe a month,” Ginzburg said.

40,000 people will participate in the third phase of tests of the Russian COVID-19 vaccine

Leave a Reply

Your email address will not be published. Required fields are marked *

2 × 5 =